Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Mar 27, 2025; 17(3): 101649
Published online Mar 27, 2025. doi: 10.4254/wjh.v17.i3.101649
Smartphone-based Stroop Test, EncephalApp: What is the optimal cutoff for diagnosing minimal hepatic encephalopathy?
Ryota Masuzaki, Hirofumi Kogure
Ryota Masuzaki, Hirofumi Kogure, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo 176-8610, Japan
Author contributions: Masuzaki R wrote the paper; Masuzaki R and Kogure H designed the overall concept and outline of the manuscript; Kogure H supervised the project; all of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ryota Masuzaki, MD, PhD, Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-ku, Tokyo 176-8610, Japan. masuzaki.ryota@nihon-u.ac.jp
Received: September 23, 2024
Revised: February 4, 2025
Accepted: February 13, 2025
Published online: March 27, 2025
Processing time: 185 Days and 1.5 Hours
Core Tip

Core Tip: Jiang et al examined the diagnostic performance of EncephalApp, a smartphone-based Stroop Test, in patients with nonalcoholic liver disease. Different etiologies manifest distinct liver damage pathophysiologies, justifying the use of varied cutoffs for alcoholic and nonalcoholic cirrhotic patients. These findings should be confirmed through validation in larger patient cohorts, ideally correlated with clinical outcomes. The clinical need for noninvasive liver disease evaluations continues to be significant.